DexCom (NASDAQ:DXCM) Given New $78.00 Price Target at Mizuho

DexCom (NASDAQ:DXCM) had its price objective lifted by Mizuho from $75.00 to $78.00 in a report released on Wednesday morning, Marketbeat reports. They currently have an outperform rating on the medical device company’s stock.

A number of other brokerages have also recently commented on DXCM. Evercore ISI assumed coverage on shares of DexCom in a research note on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price objective for the company. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 16th. JPMorgan Chase & Co. decreased their price objective on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Morgan Stanley upgraded DexCom from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $63.00 to $75.00 in a report on Tuesday, December 2nd. Finally, BTIG Research cut their target price on DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average target price of $86.61.

DexCom Stock Down 0.9%

Shares of DXCM opened at $65.75 on Wednesday. The business’s 50 day moving average is $63.96 and its 200 day moving average is $74.03. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. DexCom has a 12-month low of $54.11 and a 12-month high of $93.25. The company has a market capitalization of $25.64 billion, a PE ratio of 36.53, a price-to-earnings-growth ratio of 1.42 and a beta of 1.51.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.57 by $0.04. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.45 EPS. Research analysts expect that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the transaction, the director owned 27,031 shares of the company’s stock, valued at $1,569,690.17. This trade represents a 3.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach acquired 18,200 shares of the stock in a transaction on Monday, November 10th. The stock was bought at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the transaction, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 7,866 shares of company stock worth $448,177 in the last quarter. 0.32% of the stock is owned by company insiders.

Institutional Investors Weigh In On DexCom

Several large investors have recently modified their holdings of DXCM. GAMMA Investing LLC boosted its stake in DexCom by 2.5% in the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after acquiring an additional 169 shares in the last quarter. IFP Advisors Inc grew its stake in DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after buying an additional 178 shares during the last quarter. Inspire Investing LLC increased its position in DexCom by 6.1% during the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock valued at $211,000 after buying an additional 180 shares in the last quarter. Personal CFO Solutions LLC increased its position in DexCom by 5.0% during the 3rd quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock valued at $260,000 after buying an additional 185 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. boosted its holdings in DexCom by 3.2% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock worth $411,000 after acquiring an additional 187 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.